Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication

AstraZeneca’s flagship cancer drug is adding a new indication to its fleet.

Friday afternoon, the FDA granted Tagrisso the thumbs-up in non-small cell lung cancer for patients with EGFR mutations who had undergone tumor resection and optional, standard postoperative adjuvant chemotherapy. It’s another win for the drug as a prominent rival from J&J continues to play catch-up.